GSK exec: Pharma ills require more M&A

The pharmaceutical industry faces a stark environment of rising costs and stagnant drug innovation that will ensure more acquisitions are done, as drugmakers try to offset painful and growing business pressures, GlaxoSmithKline's chief strategy officer said. Report